Equities research analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will report earnings per share (EPS) of $0.50 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Horizon Pharma’s earnings, with the lowest EPS estimate coming in at $0.47 and the highest estimate coming in at $0.53. Horizon Pharma posted earnings per share of $0.26 during the same quarter last year, which suggests a positive year-over-year growth rate of 92.3%. The business is scheduled to announce its next earnings report on Monday, November 5th.
According to Zacks, analysts expect that Horizon Pharma will report full year earnings of $1.58 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.64. For the next year, analysts expect that the business will report earnings of $1.86 per share, with EPS estimates ranging from $1.60 to $2.12. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.17. The company had revenue of $302.84 million during the quarter, compared to the consensus estimate of $275.51 million. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. Horizon Pharma’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the business posted $0.41 earnings per share.
HZNP has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price target on Horizon Pharma from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, June 18th. Piper Jaffray Companies reissued a “buy” rating and issued a $25.00 target price on shares of Horizon Pharma in a research report on Thursday, August 9th. Mizuho reissued a “buy” rating and issued a $18.00 target price on shares of Horizon Pharma in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $21.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, Zacks Investment Research raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Tuesday, July 10th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.92.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $20.63, for a total value of $204,319.52. Following the completion of the sale, the executive vice president now directly owns 28,767 shares of the company’s stock, valued at $593,463.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.90% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in HZNP. Fox Run Management L.L.C. bought a new position in shares of Horizon Pharma in the third quarter worth $475,000. United Services Automobile Association boosted its holdings in shares of Horizon Pharma by 11.0% in the second quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 2,679 shares during the period. Northern Trust Corp boosted its holdings in shares of Horizon Pharma by 16.0% in the second quarter. Northern Trust Corp now owns 2,281,798 shares of the biopharmaceutical company’s stock worth $37,787,000 after acquiring an additional 314,156 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Horizon Pharma in the second quarter worth $1,537,000. Finally, Zacks Investment Management bought a new position in shares of Horizon Pharma in the second quarter worth $2,562,000. 87.25% of the stock is owned by institutional investors and hedge funds.
Shares of HZNP opened at $18.15 on Friday. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.70 and a quick ratio of 1.63. The company has a market cap of $3.26 billion, a P/E ratio of 15.38, a price-to-earnings-growth ratio of 1.24 and a beta of 1.40. Horizon Pharma has a 12 month low of $12.55 and a 12 month high of $21.25.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Featured Article: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.